Trials / Active Not Recruiting
Active Not RecruitingNCT05326347
A Long-term Administration Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients With Schizophrenia
A Multicenter, Uncontrolled, Open-label Trial to Investigate the Long-term Tolerability, Safety, and Efficacy of Brexpiprazole Once-weekly (QW) Formulation Administered Once Weekly for 52 Weeks in Patients With Schizophrenia
- Status
- Active Not Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 190 (estimated)
- Sponsor
- Otsuka Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 74 Years
- Healthy volunteers
- Not accepted
Summary
Confirm the tolerability and safety of long-term administration of the brexpiprazole QW formulation in patients with schizophrenia
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | OPC-34712FUM/ Brexpiprazole fumarate | The treatment will begin with oral administration of 1 tablet of the brexpiprazole QW formulation. |
Timeline
- Start date
- 2022-05-31
- Primary completion
- 2025-08-01
- Completion
- 2025-09-01
- First posted
- 2022-04-13
- Last updated
- 2024-10-30
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT05326347. Inclusion in this directory is not an endorsement.